LENZ Therapeutics, Inc. - Common Stock (LENZ)
CUSIP: 52635N103
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 31,240,118
- Total 13F shares
- 24,727,156
- Share change
- +3,653,975
- Total reported value
- $725,109,733
- Put/Call ratio
- 2.7%
- Price per share
- $29.31
- Number of holders
- 113
- Value change
- +$107,969,187
- Number of buys
- 76
- Number of sells
- 31
Quarterly Holders Quick Answers
What is CUSIP 52635N103?
CUSIP 52635N103 identifies LENZ - LENZ Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 52635N103:
Top shareholders of LENZ - LENZ Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
3/4/5
|
Company · Director, 10%+ Owner |
13%
|
4,178,823
|
$107,437,539 | — | 31 Mar 2025 | |
| Alpha Wave Global, LP |
13F
|
Company |
12%
|
3,612,211
|
$92,869,945 | — | 31 Mar 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
4.8%
|
1,511,932
|
$38,871,772 | — | 31 Mar 2025 | |
| EcoR1 Capital, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,538,446
|
$34,836,860 | — | 06 Jan 2023 | |
| Samsara BioCapital, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,497,067
|
$34,668,033 | — | 11 Apr 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.8%
|
1,199,462
|
$30,838,169 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
3.7%
|
1,166,517
|
$29,991,160 | — | 31 Mar 2025 | |
| 72 Investment Holdings, LLC |
13F
|
Company |
3.3%
|
1,017,751
|
$26,166,378 | — | 31 Mar 2025 | |
| SECTORAL ASSET MANAGEMENT INC |
13F
|
Company |
3.1%
|
977,245
|
$25,124,969 | — | 31 Mar 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
2.8%
|
863,389
|
$22,197,731 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2.7%
|
852,244
|
$21,911,203 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.5%
|
766,940
|
$19,718,027 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
2.1%
|
667,164
|
$17,152,786 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.7%
|
537,738
|
$13,825,244 | — | 31 Mar 2025 | |
| Samsara BioCapital, LLC |
13F
|
Company |
1.7%
|
526,390
|
$13,533,487 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.2%
|
360,392
|
$9,268,477 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.98%
|
306,978
|
$7,893,000 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.92%
|
287,356
|
$7,387,923 | — | 31 Mar 2025 | |
| Versant Venture Capital VII, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,598,789
|
$6,523,059 | — | 21 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.6%
|
188,744
|
$4,852,608 | — | 31 Mar 2025 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.56%
|
176,166
|
$4,529,228 | — | 31 Mar 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.45%
|
142,113
|
$3,653,725 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.45%
|
140,954
|
$3,623,927 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.4%
|
124,046
|
$3,189,223 | — | 31 Mar 2025 | |
| SCOGGIN MANAGEMENT LP |
13F
|
Company |
0.32%
|
100,000
|
$2,571,000 | — | 31 Mar 2025 | |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC |
13F
|
Company |
0.27%
|
83,172
|
$2,138,352 | — | 31 Mar 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.27%
|
83,082
|
$2,136,038 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.26%
|
81,139
|
$2,086,084 | — | 31 Mar 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.25%
|
77,275
|
$1,986,740 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.21%
|
67,037
|
$1,723,522 | — | 31 Mar 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.21%
|
66,030
|
$1,697,632 | — | 31 Mar 2025 | |
| Vivaldi Capital Management LP |
13F
|
Company |
0.19%
|
59,252
|
$1,523,369 | — | 31 Mar 2025 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
0.16%
|
49,622
|
$1,276,000 | — | 31 Mar 2025 | |
| HARBOR CAPITAL ADVISORS, INC. |
13F
|
Company |
0.16%
|
48,616
|
$1,250,000 | — | 31 Mar 2025 | |
| Phil Gutry |
3/4/5
|
CHIEF BUSINESS OFFICER |
—
class O/S missing
|
299,941
|
$1,223,759 | — | 11 Apr 2022 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.14%
|
42,230
|
$1,085,733 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.13%
|
41,781
|
$1,074,042 | — | 31 Mar 2025 | |
| BBR PARTNERS, LLC |
13F
|
Company |
0.13%
|
40,000
|
$1,028,400 | — | 31 Mar 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.11%
|
34,828
|
$895,428 | — | 31 Mar 2025 | |
| Katherine V Stultz |
3/4/5
|
CHIEF OPERATING OFFICER |
—
mixed-class rows
|
305,954
mixed-class rows
|
$881,362 | — | 24 Jun 2021 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.1%
|
30,488
|
$783,846 | — | 31 Mar 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.1%
|
30,405
|
$781,713 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.09%
|
28,694
|
$737,723 | — | 31 Mar 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.09%
|
27,935
|
$718,209 | — | 31 Mar 2025 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.09%
|
27,829
|
$715,000 | — | 31 Mar 2025 | |
| Verition Fund Management LLC |
13F
|
Company |
0.09%
|
27,569
|
$708,799 | — | 31 Mar 2025 | |
| KESTRA PRIVATE WEALTH SERVICES, LLC |
13F
|
Company |
0.09%
|
27,304
|
$701,986 | — | 31 Mar 2025 | |
| Lisanti Capital Growth, LLC |
13F
|
Company |
0.08%
|
25,665
|
$659,847 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.08%
|
24,401
|
$627,349 | — | 31 Mar 2025 | |
| Delta Investment Management, LLC |
13F
|
Company |
0.08%
|
24,001
|
$617,066 | — | 31 Mar 2025 |
Institutional Holders of LENZ Therapeutics, Inc. - Common Stock (LENZ) as of Q2 2025
As of 30 Jun 2025,
LENZ Therapeutics, Inc. - Common Stock (LENZ) was held by
113 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,727,156 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Alpha Wave Global, LP, Paradigm Biocapital Advisors LP, BlackRock, Inc., VANGUARD GROUP INC, ADAGE CAPITAL PARTNERS GP, L.L.C., 72 Investment Holdings, LLC, SECTORAL ASSET MANAGEMENT INC, TANG CAPITAL MANAGEMENT LLC, and UBS Group AG.
This page lists
113
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
105
Q2 2025 holders
113
Holder diff
8
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.